26 July 2021

AIM share code: DVRG

Deepverge PLC

("Deepverge" or "Company")

Result of Annual General Meeting

Following today's Annual General Meeting ("AGM"), convened by the Notice of AGM dated 2 July 2021, DeepVerge plc is pleased to announce that all resolutions set out in the Notice of AGM were approved by shareholders.

The results of the poll for each resolution were as follows:

Resolution

For

% For

Against

% Against

Withheld

1. The Company's annual accounts for the 12 months ended 31 December 2020, together with the directors' report and auditor's report thereon, be received and adopted.

34,372,474

99.9%

9,700

0.028%

28,951

2. To re-appoint Jeffreys Henry LLP as auditors.

34,380,263

99.9%

1,611

0.005%

29,251

3. To determine the remuneration of the auditors.

34,372,752

99.9%

11,044

0.032%

27,329

4. To re-elect Nigel Burton as a director of the Company.

34,368,338

99.9%

13,611

0.040%

29,176

5. To re-elect Camillus Glover as a director of the Company.

34,368,129

99.9%

13,820

0.040%

29,176

6. To authorise the directors to allot shares pursuant to Section 551 of the Companies Act 2006.

34,143,623

99.2%

76,963

0.224%

190,539

7. To authorise the directors to allot equity securities (within the meaning of section 560 of the Companies Act 2006) for cash as if section 561 of the Companies Act 2006 did not apply to such allotment.

34,049,883

99.0%

161,722

0.470%

199,520

As at the date of the AGM, the number of issued ordinary shares of the Company was 215,156,378 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, on a poll every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.

Following today's AGM result, a short video will be posted on the Company's website: https://www.deepverge.com/investors

For further information please visit https://www.deepverge.com/or contact:

Enquiries:

DeepVerge plc	Gerard Brandon, CEO	+44 (0) 7340 055 648

SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker/James Pope	+44 (0) 20 3621 4120

About DeepVerge

DeepVerge plc is a vertically integrated business. It's core skin and human testing technology is built on a clinical based eco-system. Collaboration partners in artificial intelligence, clinical research, medical device and life science contribute to the service management platform. This allows skin-care, health-care, nutritional, pharmaceutical manufacturers and cosmetic companies to test consumer products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

The Company's own skin-care range of products and cannabinoid oils (CBD) sources have been used to test the platform that combines data analytics with access to therapeutic operational expertise offering client solutions ranging from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our laboratory grown living human tissue (Labskin).